Department of Late-Stage Oncology Biomarkers Development, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
Department of Infectious Diseases, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
Trends Mol Med. 2017 Feb;23(2):135-149. doi: 10.1016/j.molmed.2016.12.008. Epub 2017 Jan 23.
Antibodies are potent components of the immune repertoire and have been successfully exploited to treat bacterial infections. Recently an antibody-antibiotic conjugate (AAC) that combines key attributes of an antibody and antibiotic has been shown to be efficacious against Staphylococcus aureus infection. An AAC has three components: an antibiotic payload to kill bacteria, an antibody to target delivery of the payload to bacteria, and a linker attaching the payload to the antibody. With increasing understanding of the biology and pathophysiology of S. aureus, this article highlights how this knowledge has led to the design principles of an efficacious AAC, and discusses how the AAC platform could be translationally applied to treat other perilous infectious diseases.
抗体是免疫系统的重要组成部分，已成功地被用于治疗细菌感染。最近，一种抗体-抗生素偶联物（antibody-antibiotic conjugate，AAC）结合了抗体和抗生素的关键特性，已被证明对金黄色葡萄球菌感染有效。AAC 有三个组成部分：抗生素有效载荷以杀死细菌，抗体靶向将有效载荷递送至细菌，以及连接子将有效载荷连接到抗体。随着对金黄色葡萄球菌生物学和病理生理学的理解不断加深，本文强调了这方面的知识如何导致了有效 AAC 的设计原则，并讨论了 AAC 平台如何转化应用于治疗其他危险的传染病。
